practical

Proving Zantac Use — How to Obtain Pharmacy Records

Preparing your case review…
Written By
People's Justice Legal Research Team

Why Evidence of Ranitidine Use Is Essential

One of the two pillars of a Zantac cancer claim — along with the cancer diagnosis itself — is demonstrating that you used ranitidine for a qualifying period (generally 1+ years). Unlike some pharmaceutical cases where the drug has a distinctive appearance or distinctive side effects that made it memorable, ranitidine was an extremely common, widely used, and unremarkable heartburn medication that millions of people took without much thought. Many claimants can state with certainty that they used Zantac for years but cannot recall precisely when they started, which brand or dosage they used, or how frequently. This is where documentary evidence — particularly pharmacy records — becomes essential.

Prescription Pharmacy Records — The Gold Standard

If you received prescription-strength ranitidine (150 mg or 300 mg by prescription), your pharmacy has a record of every fill. Major pharmacy chains — CVS, Walgreens, Rite Aid, Walmart Pharmacy, Costco Pharmacy, and most independent pharmacies — maintain complete fill histories for patients. These records are medical records accessible to patients under HIPAA. To obtain your records, your attorney will provide a HIPAA authorization form that you sign, allowing the pharmacy to release your prescription history to the attorney. Records can typically be obtained going back 7-10 years, and some chains have records going back further. These records show the drug name (ranitidine or Zantac), dosage, dispensing date, prescribing physician, and number of days supply — creating a detailed chronological proof of prescription use.

OTC Purchase Records — Loyalty Cards and Insurance Claims

Many Zantac users purchased OTC Zantac (available without prescription since 1996) at major retailers. OTC purchases can be documented through: pharmacy loyalty card purchase histories (CVS ExtraCare, Walgreens myWalgreens, Rite Aid Wellness+ members have itemized OTC purchase records linked to their accounts); health insurance claims data (some insurance plans covered OTC ranitidine under HSA/FSA plans, leaving a claims trail); and credit card or bank statements showing purchases at pharmacies or retail stores that correlate with ranitidine availability on the shelves. While OTC records are generally less comprehensive than prescription records, they can provide important corroborating evidence, especially when combined with patient testimony and physician records documenting OTC use recommendations.

Physician Records and Medical History Documentation

Physician records and medical histories frequently document ranitidine use even for OTC purchases, because medication reconciliation is a standard part of patient intake in medical practice. Primary care physician records, gastroenterology consultation notes, and hospital admission medication lists often include ranitidine as a listed active medication or medication history. Electronic health records (EHRs), which became widely adopted after 2014, are particularly likely to include complete medication history including OTC medications. Your attorney will subpoena or request via HIPAA authorization all primary care and specialist records that may contain medication history references. These records can corroborate or supplement pharmacy records to establish the duration of ranitidine use.

FAQ

Frequently Asked Questions

See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
Related Topics

Related Pages

Zantac NDMA Contamination Explained

NDMA contamination in Zantac is not an external manufacturing defect — it is an inherent property of the ranitidine molecule itself. Ranitidine is chemically unstable and generates NDMA as a degradation product, and additional NDMA is produced inside the human body during ranitidine metabolism. This made Zantac fundamentally dangerous regardless of which manufacturer produced it.

ndmaranitidine-chemistryzantac-contamination
Learn more

The Valisure Study — How the NDMA Problem Was Discovered

Valisure LLC, an independent pharmaceutical testing laboratory in New Haven, Connecticut, discovered the NDMA problem in ranitidine in 2019 and filed a Citizen Petition with the FDA that triggered the events leading to the April 2020 market withdrawal. Valisure's methodology was initially contested but has been substantially vindicated by subsequent independent research.

valisurecitizen-petitionndma-testing
Learn more

Zantac Settlement Expectations — State Court Litigation 2026

Zantac state court litigation in 2026 is in an active but early phase compared to fully mature mass torts. Bellwether trials in Delaware will begin to establish settlement values for the broader case pool. Settlement ranges of $200,000 to $3,000,000 are estimated for qualifying claims, with strong Stage IV/wrongful death cases commanding the highest values. Do not expect quick settlements — state court mass torts typically take years.

zantac-settlementmass-tort-timelinebellwether-trials
Learn more

Zantac Statute of Limitations — State-by-State 2026 Analysis

The statute of limitations for Zantac cancer claims varies by state, typically 2 to 3 years from the date of cancer diagnosis or from when the claimant knew or should have known of the Zantac-cancer connection (the discovery rule). The April 2020 FDA withdrawal is often cited as the constructive notice date. Claimants with diagnoses from 2022 onward and those who can show delayed discovery may still have timely claims in 2026.

statute-of-limitationsdiscovery-rulezantac-sol
Learn more

Cancers Covered by Zantac Litigation

Six cancer types are the primary qualifying diagnoses in active Zantac state court litigation in 2026: bladder, stomach, colorectal, esophageal, breast, and prostate cancers. Bladder and gastrointestinal cancers have the most robust scientific and epidemiological support. Strength of causation evidence and state court acceptance varies by cancer type, and an attorney can evaluate your specific diagnosis.

qualifying-cancersbladder-cancerstomach-cancer
Learn more

Zantac and Bladder Cancer

Bladder cancer is the cancer most strongly and consistently linked to NDMA exposure from ranitidine. NDMA is excreted in urine, directly bathing the bladder epithelium in the carcinogen. Bladder cancer carries a high recurrence rate even after successful treatment, meaning lifetime surveillance and repeat procedures create substantial ongoing medical costs that factor significantly into claim values.

bladder-cancerurothelial-carcinomacystoscopy
Learn more

Zantac Federal MDL Dismissal — What Happened

The federal MDL in the Southern District of Florida was dismissed in November 2022 after Judge Robin Rosenberg excluded all of the plaintiffs' general causation experts under the Daubert standard. This ruling applies only to federal court. It does not bind state courts. Active Zantac litigation continues in Delaware and California state courts in 2026 under different evidentiary standards.

federal-mdldaubertmdl-dismissal
Learn more

Zantac State Court Litigation — Delaware and California 2026

Following the closure of the federal MDL in November 2022, Zantac litigation has continued and grown in state courts. Delaware Superior Court is the most active venue, with thousands of consolidated cases proceeding under coordinated case management orders. California state courts have also produced favorable rulings for plaintiffs. State court proceedings are independent of the federal MDL and proceed on their own timelines in 2026.

delaware-superior-courtcalifornia-state-courtbellwether-trials
Learn more

Zantac Eligibility Requirements

To qualify for a Zantac cancer claim in 2026, you generally need: (1) at least 1 year of regular Zantac or ranitidine use; (2) a diagnosis of a qualifying cancer type; (3) a medically plausible timeline between use and diagnosis; and (4) a claim that falls within your state's statute of limitations. State court filings are active in Delaware and California.

zantac-eligibilityqualifying-useranitidine-use-requirements
Learn more

Zantac Brand vs. Generic — All Manufacturers Are Liable

The NDMA problem is inherent to the ranitidine molecule, not to any specific manufacturer or formulation. Branded Zantac (Sanofi, and previously GSK and Pfizer), generic ranitidine from Boehringer Ingelheim and others, and all store-brand versions carry the same risk. All ranitidine manufacturers are named defendants in Zantac litigation.

sanofigskpfizer
Learn more

FDA Zantac Market Withdrawal — April 2020

On April 1, 2020, the FDA formally requested that all ranitidine manufacturers withdraw their products from the U.S. market. This unprecedented action — covering both prescription and OTC products from all manufacturers — marked the FDA's conclusion that the NDMA problem in ranitidine was unfixable and that ranitidine products posed an unacceptable cancer risk for consumers.

fda-market-withdrawalfda-recallapril-2020
Learn more
Parent Case

Zantac / Ranitidine (NDMA Cancer) Lawsuit

Ranitidine, sold under the brand name Zantac by Sanofi and previously by GSK, Pfizer, and Boehringer Ingelheim, was one of the most prescribed heartburn and acid reflux medications in history. In 2019, the independent pharmaceutical testing laboratory Valisure discovered that ranitidine is inherently unstable and produces NDMA — N-nitrosodimethylamine, a probable human carcinogen — at levels up to 304,500 nanograms per tablet. The FDA acceptable daily intake limit for NDMA is 96 nanograms. In April 2020, the FDA requested that all manufacturers withdraw ranitidine products from the U.S. market. Consumers who took Zantac regularly for a year or more and subsequently developed bladder, stomach, colorectal, breast, prostate, or esophageal cancer may have viable legal claims. A federal MDL in the Southern District of Florida was dismissed in November 2022 when Judge Robin Rosenberg excluded plaintiffs' general causation experts under Daubert, finding their methodologies unreliable. However, that ruling applies only to federal court and does not bind state courts. Litigation continues in Delaware Superior Court and California state courts in 2026, where different expert standards and case-specific evidence can support claims.

View full case overview